MAZE THERAPEUTICS, INC. Stock-Based Compensation
MAZE THERAPEUTICS, INC. (MAZE) reported Stock-Based Compensation of $16.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.19M, a 183.81% increase year-over-year.
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.11M, a 120.37% increase year-over-year.
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $6.07M, a 113.01% increase year-over-year.
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.86M, a 64.92% increase year-over-year.
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $16.40M, a 70.02% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $9.65M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.30M 10-Q · filed 2026-08-11 | $22.37M derived: sum of 3 quarters · filed 2026-08-11 | $26.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.11M 10-Q · filed 2026-05-12 | $13.18M derived: sum of 2 quarters · filed 2026-05-12 | $17.05M derived: sum of 3 quarters · filed 2026-05-12 | $20.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.94M derived: sum of 2 quarters · filed 2026-03-25 | $13.17M derived: sum of 3 quarters · filed 2026-08-11 | $16.40M 10-K · filed 2026-03-25 |
| 2025-09-30 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.10M derived: sum of 2 quarters · filed 2026-08-11 | $10.33M 10-Q · filed 2025-11-06 | $13.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.46M 10-Q · filed 2026-08-11 | $9.31M derived: sum of 3 quarters · filed 2026-08-11 | $11.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.23M 10-Q · filed 2026-05-12 | $6.08M derived: sum of 2 quarters · filed 2026-05-12 | $8.42M derived: sum of 3 quarters · filed 2026-05-12 | $10.56M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $5.19M derived: sum of 2 quarters · filed 2026-03-25 | $7.34M derived: sum of 3 quarters · filed 2026-03-25 | $9.65M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.49M derived: sum of 2 quarters · filed 2025-11-06 | $6.79M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.45M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $2.31M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |